title: Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
abstract: Dermatologic manifestations from therapy with imatinib are well known and frequently include hypopigmentation, and less commonly, hyperpigmentation. There have been few reports of oral hyperpigmentation. We present a case of palatal melanosis related to imatinib therapy for chronic myelogenous leukemia. This case is reported to add to the sparse literature concerning mucosal reactions related to this medication.
authors.affiliation: University of Toronto, Sunnybrook Health Sciences Center, Department of Dentistry.
authors.forename: Michelle
authors.initials: M
authors.lastname: Wong
authors.forename: Shachar
authors.initials: S
authors.lastname: Sade
authors.forename: Melanie
authors.initials: M
authors.lastname: Gilbert
authors.forename: Hagen B E
authors.initials: HB
authors.lastname: Klieb
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008543:Melanins / Q000032:analysis; D008548:Melanosis / Q000139:chemically induced* / Q000473:pathology; D009059:Mouth Diseases / Q000139:chemically induced* / Q000473:pathology; D021362:Palate, Hard / Q000473:pathology*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D008543:Melanins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate